Novocure Ltd

10 hours ago · zacks.com

Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

23 hours ago · fool.com

NovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.

3 days ago · seekingalpha.com

NovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO & Director Christoph Brackmann - Chief Financial Officer Uri Weinberg - Chief Innovation Officer & Chief Medical Officer Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Tanmay Patwardhan - JPMorgan Chase & Co. Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the NovoCure Q3 2026 Earnings Call. [Operator Instructions] Please note, this call may be recorded.

4 days ago · marketbeat.com

NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjusted EBITDA outlook while acknowledging commercial headwinds for its newer Optune Pax therapy in the United States.

4 days ago · zacks.com

NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.

5 days ago · businesswire.com

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem's investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou.

20 days ago · seekingalpha.com

NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption accelerating, especially for new launches like Optune Pax. Valuation multiples are below sector medians (EV/Sales 2.05x vs. 3.66x), while the pipeline and upcoming Optune Mya launch offer significant upside.

1 month ago · businesswire.com

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. “The approval of Optune Pax provides a promising new treatment option for locally advanced pancreatic cancer, a disease with an urgent need for effective therapies,” said Makoto Ueno, MD, PhD, D.

2 months ago · marketbeat.com

NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.

2 months ago · seekingalpha.com

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript